Enanta Pharmaceuticals | سود ناخالص در فروش





سود ناخالص در فروش تغییر دادن تاریخ
AbbVie USD 10.47B 605M 2025-09
Amgen USD 6.48B 307M 2025-09
Anika Therapeutics USD 14.68M 9.46M 2025-03
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD -88.88M 202.74M 2024-12
Biogen USD 1.65B 34.6M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 23.35M 1.6M 2024-09
Immunic 0 0 2025-03
Incyte USD 1.39B 118.68M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 16.6B 118M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.82B 695M 2025-09
Novavax USD 23.89M 239.21M 2024-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12


Enanta Pharmaceuticals سود ناخالص در فروش - ارزش های فعلی، داده های تاریخی، پیش بینی، آمار، نمودار و تقویم اقتصادی - Mar 2026.